A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder
Patients with superficial transitional cell carcinoma of the bladder will be treated with
intravesical suramin in a phase I dose escalating study. The toxicity of suramin
administered in this fashion will be evaluated.
Interventional
Endpoint Classification: Safety Study, Primary Purpose: Treatment
United States: Federal Government
940098
NCT00001381
March 1994
December 2000
Name | Location |
---|---|
National Cancer Institute (NCI) | Bethesda, Maryland 20892 |